Utilising an interleukin-12 plasmid: a novel COVID-19 vaccine
Dr Bernard Fox from Providence Cancer Institute explains how OncoSec’s CORVax12 vaccine works to potentially combat COVID-19.
List view / Grid view
Dr Bernard Fox from Providence Cancer Institute explains how OncoSec’s CORVax12 vaccine works to potentially combat COVID-19.
A rise in biotechnology R&D activities is expected to drive the growth of the immuno-oncology assay market, with a CAGR of 10.6 percent.
By culturing blood cells with mesenchymal stromal cells (MSCs), researchers induced the production of cells with the same functionality as Tregs.
A study has shown that cannabidiol (CBD) slows cancer cell growth and is toxic to human glioblastoma cell lines, presenting a possible treatment.
Scientists from Singapore have argued that T-cell immunotherapy can be used to combat a range of infectious diseases, including COVID-19.
The developers of a novel method to create immunological assay probes for screening T cells has leveraged their new protocol against COVID-19.
Using cyro-electron microscopy, researchers have imaged the binding site between a molecule and the tumour suppressor protein PP2A, enabling optimisation of the drug compound.
Researchers demonstrated NSPP completely prevented cognitive decline in mice treated with radiation for patient-derived glioblastomas.
Researchers have used the genome of Erysimum cheiranthoides (wormseed wallflower) to understand how plants biosynthesise cardenolides.
Researchers have created a new kind of immunotherapy using the interleukin-27 (IL-27) cytokine to effectively combat tumours in vitro and in vivo.
The loss of RXR function, a molecular mechanism which determines the identity macrophages, has been revealed as a drug target for cancers in serous cavities.
Researchers have developed two small molecules which target two components of the circadian rhythm and could be used to lengthen the body clock.
Researchers have developed a new CAR T-cell therapy that targets an antigen called glycipan-1 (GPC1), showing efficacy at fighting solid tumours in mice.
Researchers have optimised PROTAC substances to degrade and dispose of proteins that support cancers, by customising their structure and selecting the best ligases.
A new discovery about how cancer cells exchange contents with fibroblasts presents a new oncologic drug target, according to the researchers.